# KPV: Research Overview — Cowboy Up Peptide > A literature summary of KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH studied for gut mucosal healing and anti-inflammatory effects. Covers PepT1 uptake, NF-kB suppression and the preclinical-only evidence base. A three-amino-acid fragment of alpha-MSH that retains the parent hormone's anti-inflammatory activity while dropping its pigment effect — studied most in models of gut inflammation. ## The short version KPV is one of the smallest peptides in the research literature — just three amino acids: lysine, proline, valine. It is the tail end of a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. The notable thing about this particular tail is that it preserves the full hormone's *anti-inflammatory* activity while leaving behind its skin-darkening (pigmentary) effect [10]. Unlike BPC-157, KPV does not build tissue or grow blood vessels — its role in the research is *calming* the inflammatory signals that can prevent a wound or irritated mucosa from healing. The research is concentrated in animal models of colitis and in cell cultures; there are no published human clinical trials of KPV at all [8]. It is sold for laboratory research only, is not an approved drug or dietary supplement, and this page lists no human dose. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11-13 — the C-terminal, or tail, sequence — of alpha-MSH. Because it derives from a melanocortin hormone you will sometimes see it written as alpha-MSH(11-13). Its molecular formula is C16H30N4O4. Its defining feature in the literature is that it preserves anti-inflammatory activity *without* the melanogenic (pigment-producing) action of the full hormone — which is why researchers position it as an anti-inflammatory alternative to alpha-MSH rather than a tanning compound [10]. KPV has no approved drug or dietary-supplement status in any major jurisdiction and is available only as a research chemical. ## How it works KPV dampens inflammation by suppressing two major inflammatory switches inside cells: the transcription factor *NF-kB* and the *MAP-kinase* signaling pathways. Quieting these pathways reduces the production of pro-inflammatory cytokines — signaling proteins such as IL-1beta and TNF-alpha — that sustain and amplify an inflammatory response [8]. There is a particularly interesting delivery story in the gut. KPV is small enough to be carried directly into intestinal epithelial cells by a transporter called *PepT1* (gene SLC15A1), a di/tripeptide transport protein. Crucially, PepT1 is upregulated in inflamed intestinal tissue — meaning the very route that brings KPV in is more active precisely where the inflammation is [8]. At nanomolar concentrations, KPV transported this way reduced NF-kB and MAPK activation and lowered cytokine secretion in both epithelial cells and immune cells [8]. A separate finding adds mechanistic nuance: KPV's anti-inflammatory effect was retained even in mice lacking the MC1R receptor, indicating that it acts through an MC1R-independent mechanism rather than the classic melanocortin signaling pathway [9]. ## What the research shows *Mechanism in cells and mice.* The foundational 2008 study demonstrated PepT1-mediated KPV uptake into human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, with nanomolar KPV inhibiting NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion; orally administered KPV also reduced the severity of two chemically induced colitis models (DSS and TNBS) in mice [8]. *MC1R-independent colitis recovery.* In a separate murine colitis study, KPV produced earlier recovery, stronger regain of body weight, reduced inflammatory infiltrate and lower myeloperoxidase activity — a marker of neutrophil recruitment. Critically, effects persisted in MC1R-deficient mice, confirming the receptor-independent anti-inflammatory route [9]. *Breadth review.* A 2008 comprehensive review of alpha-MSH and related tripeptides documents KPV and relatives showing protective effects across multiple inflammatory models — gut, skin, eye, airway, joints, fever and organ-injury — and delineates KPV specifically as the anti-inflammatory option that lacks pigmentary action [10]. *Targeted delivery.* Because free KPV is a fragile, peptidase-susceptible molecule, much recent work is formulation science. Hyaluronic-acid-functionalized nanoparticles carrying KPV, delivered orally in a chitosan/alginate hydrogel, reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing in DSS-treated mice [7]. A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic colitis in mice beyond either agent alone, restoring tight-junction proteins and reducing inflammatory cytokines [6]. *Corneal wound healing.* Topical alpha-MSH(11-13) — KPV — accelerated corneal epithelial wound healing in rabbits via a nitric-oxide-dependent mechanism; by 60 hours, 8 of 8 corneas treated with KPV were completely re-epithelialized versus none in the placebo group [11]. *Mechanistic distinction.* A 2003 dissection of alpha-MSH peptide fragments found that KPV reduced leukocyte accumulation in a peritonitis model but, unlike core MSH peptides, did not suppress macrophage cytokine release — suggesting its anti-inflammatory action is mechanistically distinct, likely directed through inhibition of IL-1beta function rather than the classic melanocortin route [12]. ## Reported effects, cautions & safety The cautions for KPV are dominated by one straightforward fact: the entire evidence base is preclinical. - *No human trials.* There are no published human clinical trials of KPV; the full efficacy literature is in vitro and animal (chiefly murine colitis), leaving human dosing, efficacy and safety entirely unestablished [8]. - *No validated human pharmacokinetics.* Free KPV is a small, peptidase-labile tripeptide. How it behaves in the human body after any route of administration is unknown — which is why the field's recent effort concentrates on delivery formulations [7]. - *Marketing outpaces evidence.* Promotion of KPV for gut health, skin, or general anti-inflammatory use runs ahead of an evidence base that is mechanistic and preclinical, not clinical [10]. - *Not a tanning peptide.* Although KPV derives from alpha-MSH, it should be distinguished from melanocortin agonists used for skin pigmentation; its defining property in the literature is anti-inflammatory activity *without* the pigment effect [10][12]. - *Citation hygiene.* PMID and DOI errors are common in secondary web sources covering KPV; identifiers should be verified at PubMed rather than copied from aggregators [10]. - *Research-use status only.* KPV is available from chemical suppliers for laboratory research only. It is not an approved drug or dietary supplement in any major jurisdiction. ## Where it fits in recovery research KPV is the other half of a complementary pair. Where [BPC-157](/bpc-157) intervenes at the supply side of repair — stimulating the new blood vessels that bring resources into a wound — KPV works the resolution side: quieting the inflammatory signaling that can keep a tissue from healing even once the repair machinery is available [8]. Its evidence is the more uniformly preclinical of the two (no human trials at all), yet its mechanism is among the most precisely mapped on this desk, traced from PepT1 uptake through NF-kB suppression to an MC1R-independent anti-inflammatory route [8][9]. For the side-by-side view, see the [comparison page](/compare). ![KPV tripeptide research illustration — abstract tissue and mucosal repair motifs in cold gunmetal cyan](/images/kpv.webp) --- A literature digest on repair-peptide research — study findings in plain language, citations intact, nothing for sale and no dosing advice.